Clinical Trial Update: A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of osimertinib and S-1 in treatment-resistant EGFR-mutant non-small cell lung cancer; the study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: NSCLC | Phase 2 | Status: ACTIVE_NOT_RECRUITING